Do you want to read an article? Please log in or register.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Psoriatic Arthritis
Related content
Rheumatoid Arthritis
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
N Engl J Med.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y
doi: 10.1056/NEJMoa1608345.
Rheumatoid Arthritis
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial
Arthritis Rheumatol.
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC
doi: 10.1002/art.41032.
COMMENTED
Psoriatic Arthritis
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
★ 1
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1136/annrheumdis-2019-216500.
Psoriatic Arthritis
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate
Ann Rheum Dis.
van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D
doi: 10.1136/annrheumdis-
Psoriatic Arthritis
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Lancet.
McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L, EXCEED Study Group
doi: 10.
COMMENTED
Psoriatic Arthritis
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Patients Treated with Tofacitinib or Adalimumab
J Rheumatol.
van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L
doi: 10.3899/jrheum.180971.
Psoriatic Arthritis
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
N Engl J Med.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C1, Menon S, Hendrikx T, Kanik KS
doi: 10.1056/NEJMoa1615977.
Rheumatoid Arthritis
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Ann Rheum Dis.
Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME
doi: 10.1136/
Rheumatoid Arthritis
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialv
Lancet.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators
doi: 10.1016/